Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external ...

Horsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration ...

The study of immuno-metabolism explores how metabolic processes influence the immune system, particularly via antigen presentation. Recent findings reveal ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles. These ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles.

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...